Revival of the cryopreserved dead
People frozen at the moment of death, stored for centuries, and later thawed, repaired and restored to life in a future with better medicine.
In shortRevival of the cryopreserved dead, from A World Out of Time (Larry Niven, 1976) and Revelation Space (Alastair Reynolds, 2000), is at technology readiness level 1 of 9 (basic principles observed) at its weakest link. Held back by Cell-by-cell in-vivo repair and Desktop molecular assembler. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $13B–138B (a floor; some parts are priced only to early research).
Jaybee Corbell is a corpsicle - frozen in 1970 after terminal cancer, thawed three centuries later by the State, his mind restored into a donor body and sent out as a rammer pilot.
Long-dead or dying individuals held in cryogenic storage are revived generations later as a routine, if risky, procedure.
Closest todayCryonics organizations preserve bodies today using vitrification agents; no mammal, and no mammalian brain, has been cryopreserved and functionally revived, and current preservation is a one-way procedure.
Dependency stack
- Preservation happens after ischemic injury, so revival means repairing damage that was present before cooling, cell by cell
- No way to read the internal state of a living cell without destroying it
- A human body has roughly 3x10^13 cells, so any per-cell procedure needs a throughput no proposed system approaches
- Molecular-scale positional control in a warm, crowded, aqueous environment is unsolved
- Energy supply and waste handling for billions of simultaneously operating devices is unaddressed
plausibleTRL 1- Desktop molecular assemblerbottleneckRebuilding damaged structures implies atomically precise construction under program control
- Requires positional mechanosynthesis at ~10^6 operations/s per tool and ~10^9 parallel tools
- Heat dissipation and error correction for atomically precise assembly at kilogram scale
- No bootstrap path from today's scanning probes to self-built nanoscale tools
plausibleTRL 1- The basic operation the assembler repeats billions of times
✕3 blockers›
- Tool-tip reactions are cryogenic, UHV and succeed probabilistically; no reaction set with >99.9% per-step fidelity
- No demonstrated tooltip recharge cycle, so each tip makes only a handful of bonds
- Throughput of ~1 operation per minute is ~20 orders of magnitude short of bulk manufacturing
plausibleTRL 2 - Most credible bootstrap path is self-assembling designed protein machinery that positions reactants
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- Repair requires devices that sense and act inside tissue, not just circulate
✕4 blockers›
- No onboard power source or computation - behavior is limited to a single preset molecular trigger
- Immune clearance and protein-corona formation remove most devices within hours
- Actuation cannot overcome blood flow or cross tissue barriers on command
- External actuation rigs used in labs do not fit clinical imaging suites
TRL 3- Nucleic-acid scaffolds are the only programmable construction material at this scale today
✕3 blockers›
- Nuclease degradation and cation-dependent unfolding limit in-vivo lifetime to hours without protective coatings
- Structures generate piconewton forces - far below what mechanical work on cells would need
- No onboard logic beyond a handful of strand-displacement states
TRL 5 - A device you cannot localize in the body cannot be steered or verified
✕3 blockers›
- Optical scattering caps high-resolution imaging at a few millimetres of tissue depth
- MRI gives depth but not video-rate cell-scale resolution, and excludes magnetic actuation hardware
- Tracking swarms rather than single objects has no demonstrated method
TRL 5 - Sensing and effector modules are designed proteinsTRL 6
- Repair must be verified in place, not inferred from outcomesTRL 5
- Revival is impossible unless whole-body vitrification and rewarming can be reversed at all
✕4 blockers›
- Cryoprotectant must reach every tissue through a circulation that stops working as it cools
- Different tissues need different agent concentrations and cooling rates, so no single protocol fits a whole body
- Rewarming a 70 kg body uniformly faster than devitrification has no demonstrated mechanism
- Whole-brain functional recovery after vitrification has never been shown in any species
plausibleTRL 2- A body is a set of organs that must each survive the same protocol
✕4 blockers›
- Rewarming rate must exceed the devitrification threshold everywhere at once - heating uniformity gets worse with volume
- Thermal-stress cracking appears in organ-scale samples below the glass transition
- Nanoparticle loading and complete post-warming washout are unproven in large vasculature
- Brain has never been vitrified and recovered functionally in any species
TRL 4- Vitrification only happens if ice is suppressed throughout the tissue
✕3 blockers›
- Cryoprotectant concentrations that prevent ice (over 50 percent w/v) are chemically toxic over the hours needed to load a large organ
- Perfusion is uneven - poorly vascularized regions receive too little agent and nucleate ice
- Devitrification during rewarming happens faster than agents can suppress in large volumes
TRL 5- Designed ice-binding and antifreeze proteins are the main route to blocking ice at lower chemical toxicityTRL 6
- The brain is the organ whose information must survive, and it sets the protocol's hardest constraint
✕3 blockers›
- Ischemic damage starts within minutes of circulatory arrest, before perfusion can begin
- Aldehyde fixation may destroy molecular state (phosphorylation, receptor conformation) that could carry memory
- No assay proves preserved tissue still contains the information an emulation would need
TRL 4 - Whole-body loading needs far lower toxicity per unit ice suppression than organ work doesTRL 5
- Whatever is preserved must still contain the structural and molecular information the person consisted ofTRL 4
- Each organ must be recoverable, not merely intact on histologyTRL 4
- supportingCausal mechanisms of agingPatients are preserved old and sick, so revival implies rejuvenation as well as repair
✕3 blockers›
- No validated surrogate biomarker of biological age, so any whole-body rejuvenation claim needs decade-long outcome trials
- Hallmarks of aging are correlated; interventions cannot yet be attributed to a specific causal node
- Mouse lifespan results have repeatedly failed to transfer to longer-lived species
TRL 3
Who could unlock it
- Across several requirements:
- Brain Preservation Foundation 2
- John Bischof 2
- NSF ATP-Bio 2
- Wei GaoResearcher, California Institute of TechnologyBuilt bioresorbable acoustic microrobots that were ultrasound-tracked and magnetically steered to shrink bladder tumours in mice (Science Robotics, 2024), then simplified them into self-targeting bubble bots (Nature Nanotechnology, February 2026)
- Bjoern HoegbergResearcher, Karolinska InstitutetBuilds DNA origami devices that hide a cytotoxic peptide pattern until a tumour's acidic pH triggers display, killing tumour cells in mice (2024) - the closest thing to a conditional molecular machine acting in a body
- Bradley NelsonResearcher, Multi-Scale Robotics Lab, ETH ZurichLong-running program on magnetically actuated micro- and nanorobots and the control and imaging needed to steer them through real tissue
- Hao YanResearcher, Biodesign Center for Molecular Design and Biomimetics, Arizona State UniversityPioneer of programmable DNA origami architectures, including origami nanostructures used as triggerable drug carriers in animal models
- Robert FreitasResearcher, Institute for Molecular ManufacturingCo-author of Kinematic Self-Replicating Machines and of theoretical mechanosynthesis toolsets and nanofactory designs
- Ralph MerkleResearcher, Institute for Molecular ManufacturingCo-developed theoretical assembler and mechanosynthesis designs; co-inventor on CBN Nano's mechanosynthesis patents
- CBN Nano TechnologiesStartupOttawa company pursuing experimental tip-based mechanosynthesis as a path to nanofactories; holds Freitas/Merkle patents
- Foresight InstituteProgramNonprofit funding molecular-machine and APM research (~$1.5M grants in 2024) and awarding the Feynman Prizes
- Greg FahyResearcher, 21st Century MedicineDeveloped the M22 cryoprotectant and reported in 2026 ultrastructural and histological preservation of whole mammalian brains by vitrification without aldehyde fixation
- 21st Century MedicineCompanyThe only company doing primary cryobiology research toward reversible preservation; won the Brain Preservation Foundation small mammal prize for aldehyde-stabilised cryopreservation
- Brain Preservation FoundationProgramSet and judged the small and large mammal brain preservation prizes, which remain the only independent benchmarks in the field
- Alcor Life Extension FoundationCompanyPerforms whole-body procedures today at roughly 220 thousand dollars (neuro 80 to 90 thousand), all one-way, with no claim of demonstrated reversibility
- Robert McIntyreResearcher, NectomeDeveloped aldehyde-stabilized cryopreservation (Cryobiology 2015) and won the Large Mammal Brain Preservation Prize in 2018
- NectomeStartupAnnounced in 2026 a field protocol for whole-body preservation at subsynaptic detail, after working on the post-mortem timing problem from 2018 to 2025
- Sparks Brain PreservationCompanyNon-profit (formerly Oregon Brain Preservation) offering aldehyde-based preservation; published whole-brain fixed-tissue cryopreservation in PLOS One (2026)
- Andrew McKenzieResearcher, Sparks Brain PreservationLead on Sparks' studies of immersion fixation and aldehyde-based cryopreservation of human brains (2024-2026)
- John BischofResearcher, University of MinnesotaDirects NSF ATP-Bio and led the September 2026 result vitrifying human-scale pig kidneys for up to 366 days with function recovered on transplant
- NSF ATP-BioProgramNSF Engineering Research Center (EEC-1941543) co-led by Minnesota and Mass General Brigham, pairing the PEZ42 cryoprotectant with radiofrequency nanowarming
- Erik FingerResearcher, University of MinnesotaTransplant surgeon who reperfused the nanowarmed pig kidneys in 2026 and reported urine output on the operating table
- Mehmet TonerResearcher, Massachusetts General Brigham and Harvard Medical SchoolDeputy director of ATP-Bio, supplying the microfluidic and biopreservation side of the organ-banking effort
Beyond engineering
- Preservation can legally begin only after declaration of death, guaranteeing an ischemic interval
- Centuries-long custodial and financial arrangements with no enforcement precedent
- No consent framework for a revived person's legal identity, property or obligations